Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 Marijuana and Psychedelics industry news stories for the week of April 6th – 12th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
10. Is Cannabis an Effective Treatment for COVID-19? The Feds Want to Know and Are Offering Researchers $100K to Find Out
The Question on Everyone’s Mind: How Can We Stop the COVID-19 Pandemic?
Recently, a new question has emerged. Could cannabis play a role in helping treat Coronavirus patients? Canadian doctors are already looking into it, and the U.S. federal government just announced they’re willing to pay researchers up to $100k to find out.
READ FULL CANNABIS COVID-19 ARTICLE
9. Here’s How Psychedelic Medicine Could Help End the Opioid Epidemic Once and For All
The Opioid Crisis Has Plagued America for Decades, According to the HHS, it Kills an Estimated 130+ People Per Day
Thanks to recent advancements in psychedelic medicine, there’s renewed hope and optimism surrounding the deadly opioid epidemic. ATAI Life Sciences, DemeRx and MindMed (neo:MMED) (fra:BGHM) are waging war against opioid addiction By utilizing this one little-known Psychedelic substance.
READ FULL OPIOID EPIDEMIC ARTICLE
8. Did COVID-19 Kill The Cannabis Industry’s Merger And Acquisition Activity?
New Data as of March 20th is Showing a Nearly 67% Decrease in Merger and Acquisition Activity Compared to Last Year
With the share prices of so many Cannabis Stocks crushed down near 52-week and all-time lows, their cost of capital has greatly increased, making both capital raising and stock-based transactions far less feasible.
READ FULL CANNABIS M&A ARTICLE
7. Champignon Brands to Acquire Health Canada Licensed Psychedelic Clinic Operator AltMed
AltMed Owns 75% of a Fully Operational Ketamine Clinic Located Near Toronto, Ontario
Champignon Brands (cse:SHRM) /zigman2/quotes/217267142/composite SHRMF +2.83% (fra:496) announced it has entered into a definitive agreement to acquire 100% of AltMed Capital Corp. AltMed is a preeminent Canadian Ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer. AltMed’s Psychedelics clinic is licensed by Health Canada to dose eligible patients with Psilocybin and is the only clinic in Canada able to perform Psilocybin doses under Health Canada approval.
READ FULL CHAMPIGNON BRANDS ARTICLE
6. Oregon Sets Cannabis Sales Mark with $84.5 Million in March